To remain competitive, companies will need to focus on innovation, expand indications, and explore novel delivery mechanisms
sales, strongest profit ever in 2025 Hanmi raises oncology stakes with phase 2 belvarafenib combo in NRAS-mutant melanoma Hanmi amends Aptose merger deal, pushes shareholder vote to March and adds $11.1 mil
The STEP 1 signature had a high classification performance (internal nested cross-validation area under the curve (AUC) = 0.94), showing that semaglutide treatment results in a specific serum proteomic signature
What do doctors think about microdosing
Medication selection should consider the patient's comorbidity profile, previous medication responses, potential drug interactions, and individual preferences
Ayudar a la reduccin de grasa corporal estimulando el metabolismo y la quema de grasas